Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2002
Business Overview: A worldwide developer, manufacturer, and marketer of medical devices for less invasive procedures, operating in four geographic segments: United States, Europe, Japan, and Inter-Continental.
Key Financial Metrics
| Metric (in millions) | Q1 2002 | Q1 2001 |
|---|---|---|
| Net Sales | $675 | $654 |
| Gross Profit | $468 | $432 |
| Gross Margin | 69.3% | 66.1% |
| Operating Income | $125 | $40 |
| Net Income | $82 | $(5) |
| Diluted EPS | $0.20 | $(0.01) |
| Cash from Operations | $59 | $91 |
| Cash & Equivalents (End of Period) | $201 | $84 |
| Total Debt (Short-term + Long-term) | $1,243 | N/A |
Note: Total Debt for Q1 2002 calculated as Commercial Paper ($116M) + Bank Obligations ($218M) + Long-term Debt ($909M).
Material Changes vs. Prior Period
- Profitability Turnaround: The Company reported a net income of $82 million compared to a net loss of $5 million in Q1 2001. This improvement is driven by higher operating income ($125M vs $40M) and reduced amortization expenses.
- Revenue Growth: Net sales increased 3% to $675 million. On a constant currency basis, sales grew 6% to $696 million, offset by a $21 million adverse foreign currency impact.
- Margin Expansion: Gross margin improved to 69.3% from 66.1%, attributed to operational cost improvements from the global operations plan and product mix shifts.
- Accounting Change: Adoption of FASB Statement No. 142 resulted in an $11 million pre-tax benefit due to the cessation of goodwill amortization.
- Debt Structure: Short-term borrowings increased significantly, with commercial paper rising from $99 million (Dec 2001) to $391 million (March 2002).
Guidance, Outlook, and Risks
Management Commentary & Outlook
- Product Launches: The Company launched the Express coronary stent in international markets, anticipating a U.S. launch in H2 2002. The TAXUS drug-eluting stent program is progressing with clinical trials (TAXUS I-IV).
- Market Dynamics: Management expects NIR(R) coronary stent market share to decline in 2002 due to competition from drug-eluting stents. However, growth in non-stent cardiovascular and endosurgery products is expected to offset this.
- Restructuring: The global operations plan (plant optimization) is expected to be substantially completed in Q2 2002, with an additional $30 million in cash outlays anticipated for the remainder of the year.
- Acquisitions: Announced the acquisition of BEI Medical Systems for approximately $95 million, expected to close in Q2 2002.
Risks and Contingencies
- Patent Litigation: Significant ongoing litigation with Johnson & Johnson (Cordis) regarding the NIR(R) stent. A jury previously awarded Cordis $324 million; the court set aside damages and ordered a new trial on damages. The Company has not recorded a loss contingency.
- Supplier Dispute: Medinol Ltd., the exclusive supplier of NIR(R) stents, sent a letter purporting to terminate the supply agreement. The Company intends to challenge this.
- Regulatory & DOJ Investigation: A U.S. Department of Justice grand jury investigation continues regarding the shipment of the NIR ON(R) Ranger(TM) stent system. The Company and two officials are targets.
- Debt Refinancing: A $1 billion credit facility matures in June 2002; the Company expects to refinance this amount.
Investor Verification Checklist
- Medinol Supply Agreement: Verify the status of the dispute with Medinol Ltd. and the potential impact on NIR(R) stent supply and revenue.
- Cordis Litigation Outcome: Monitor the new trial on damages regarding the $324 million jury verdict and potential liability exposure.
- DOJ Investigation: Track developments in the Department of Justice investigation regarding the 1998 stent recall.
- Debt Maturity: Confirm the successful refinancing of the $1 billion credit facility maturing in June 2002.
- Drug-Eluting Stent Timeline: Assess the progress of the TAXUS clinical trials and the regulatory approval timeline for the U.S. launch (targeted Q4 2003).